Neurological diseases, especially degenerative diseases, have been mainly treated symptomatically with small molecule drugs. In recent years, however, the development of antibody therapeutics, nucleic acid therapeutics, and gene therapies that selectively act on specific proteins, RNA, and DNA has been underway to identify disease-modifying drugs that improve disease outcomes by acting on the underlying pathogenic mechanisms of diseases. It is expected to enable disease-modifying therapy not only for neuroimmunological and functional diseases, but also for neurodegenerative diseases caused by loss of protein function and accumulation of abnormal proteins.